Reuters logo
BRIEF-U.S. FDA approves Orexo's low dose Zubsolv for treatment of patients with opioid dependence
October 6, 2016 / 12:46 PM / in a year

BRIEF-U.S. FDA approves Orexo's low dose Zubsolv for treatment of patients with opioid dependence

Oct 6 (Reuters) - Orexo AB :

* U.S. FDA approves Orexo’s low dose zubsolv buprenorphine and naloxone sublingual tablets (CIII)

* Orexo U.S. says U.S. FDA has approved Zubsolv 0.7mg/0.18mg for treatment of patients with opioid dependence Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below